Are Analysts Bullish about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) after last week?

December 5, 2017 - By Stephen Andrade

 Are Analysts Bullish about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) after last week?

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 8 analyst reports since December 1, 2015 according to SRatingsIntel. The rating was initiated by Raymond James with “Buy” on Tuesday, September 12. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Thursday, July 21 with “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Monday, August 21. As per Monday, June 12, the company rating was maintained by Maxim Group. The stock has “Buy” rating by Maxim Group on Tuesday, December 1. Below is a list of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) latest ratings and price target changes.

15/11/2017 Broker: FBR Capital Rating: Buy New Target: $9.5
04/10/2017 Broker: B. Riley & Co Rating: Buy New Target: $9.5
12/09/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Initiate
21/08/2017 Broker: Maxim Group Rating: Buy New Target: $13.0 Maintain
12/06/2017 Broker: Maxim Group Rating: Buy New Target: $10.0000 Maintain

The stock increased 3.15% or $0.13 during the last trading session, reaching $4.13. About 156,170 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since December 5, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $137.75 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

More important recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: which released: “Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND …” on December 04, 2017, also published article titled: “Adamis Pharmaceuticals: A Rocket Counting Down To Lift-Off”, published: “Adamis Pharmaceuticals: Limited Risk, But Skeptical About Gains” on October 27, 2017. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) was released by: and their article: “Adamis Pharmaceuticals: A Rocket Still On The Launchpad” with publication date: November 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.